Medpal AI Regulatory News (MPAL)

7 April 2026

MedPal AI plc

("MedPal AI" or the "Company")

Pharmacy Operational Update

MedPal AI (AIM: MPAL, FRA: Z1N), the AI-powered, integrated digital health company, is pleased to announce a record month of pharmacy dispensing activity at its wholly owned subsidiary, MedPal Limited.

Highlights:

· Record month: 41,600 prescription items dispensed in March 2026, the highest monthly volume since operations commenced, representing growth of 27.5% month-on-month

· Zero to scale in five months: Dispensing volumes have grown from zero in October 2025 to over 41,600 items in March 2026, demonstrating rapid scaling of the Company's automated pharmacy platform

· Cumulative milestone: Total items dispensed since launch has now reached approximately 200,000, underscoring sustained adoption of the Company's NHS and private pharmacy services

· Annualised revenue: Pharmacy operations now exceed £5 million in annualised turnover based on March 2026 dispensing volumes

· Strong margins: Gross margin for March 2026 exceeded 34%, reflecting the operational leverage of the Company's automated dispensing infrastructure as volumes scale

The continued acceleration in dispensing volume demonstrates the increase in patient demand across both NHS Distance Selling Pharmacy services and private prescriptions through MedPal.clinic. The Company's technology-led cost structure continues to support strong gross margins, which in March 2026 exceeded 34%. The Directors believe that the platform has substantial capacity for further volume growth, which will deliver meaningful operating leverage as fixed costs are absorbed over a larger revenue base.

Outlook

The Board remains highly confident in the Company's growth trajectory and the significant market opportunity ahead. Key drivers of continued pharmacy growth include:

· Expanding NHS volumes: Growing patient adoption of the Company's Distance Selling Pharmacy services, supported by 24/7 automated robotic dispensing and rapid nationwide delivery

· MedPal.clinic momentum: Continued strong demand for GLP-1 weight-loss treatments, with MedPal.clinic's AI-powered triage and zero-cost consultation model providing a significant competitive advantage in a rapidly expanding UK obesity market

· Operational capacity: Substantial headroom within the Company's robotic dispensing infrastructure to accommodate significantly higher volumes without proportionate cost increases, providing a clear pathway to improved profitability

Jason Drummond, Chief Executive Officer of MedPal AI, commented:

"Dispatching over 41,000 items in March, our highest ever monthly total, is a landmark moment. In just five months, we have scaled from zero to an annualised pharmacy revenue run rate exceeding £5 million, and we have done this while delivering a gross margin of over 34% in March. This extraordinary rate of growth demonstrates the power of our vertically integrated, AI-driven model.

"Our technology-led cost structure means that as dispensing volumes grow, fixed costs are spread over a larger revenue base, driving further margin improvement. The traditional pharmacy model is being disrupted, and MedPal is leading that disruption. We look forward to updating the market on continued progress."

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014 (which forms part of domestic UK law pursuant to the European Union (Withdrawal) Act 2018). The Directors of the Company are responsible for the contents of this announcement.

Enquiries:

About MedPal AI

MedPal AI is a UK-based digital health company building the MedPal Health OS - a vertically integrated, closed-loop platform spanning AI wellness, clinical services, and automated pharmacy fulfilment. Its core app aggregates data from over 100 wearable devices and health apps (including Apple Health, Fitbit, Garmin, and Whoop) into a unified health profile, offering personalised, non-clinical lifestyle guidance through its AI wellness coach and acting as the consumer front door to the Company's clinical and pharmacy services.

Through its wholly owned subsidiary MedPal Limited, the Company operates a 24/7 AI-powered automated pharmacy distribution centre, providing nationwide NHS and private prescription services. The facility leverages BD Rowa VMAX robotic dispensing technology integrated with AI triage to deliver rapid, cost-effective medication fulfilment with same-day and next-day delivery capabilities.

MedPal AI has a partnership agreement with Epassi UK Limited, which will, for a limited time, grant exclusive, zero-cost access to the MedPal AI app across Epassi's network of 11M+ employees at major firms. The Company's LEI is 984500EDP8B0A14CBA61.

Forward Looking Statements

This announcement contains forward-looking statements relating to expected or anticipated future events and anticipated results that are forward-looking in nature and, as a result, are subject to certain risks and uncertainties, such as general economic, market and business conditions, competition for qualified staff, the regulatory process and actions, technical issues, new legislation, uncertainties resulting from potential delays or changes in plans, uncertainties resulting from working in a new political jurisdiction, uncertainties regarding the results of exploration, uncertainties regarding the timing and granting of prospecting rights, uncertainties regarding the timing and granting of regulatory and other third party consents and approvals, uncertainties regarding the Company's or any third party's ability to execute and implement future plans, and the occurrence of unexpected events.